Lansoprazole, a proton pump inhibitor, to reduce gastrointestinal inflammation via heme oxygenase-1 induction

Molecular and Cellular Pharmacology

Volumn 2, Issue 2, 2010, Pages 53-60

  Naito, Yuji ^a   Takagi, Tomohisa ^a   Yoshikawa, Toshikazu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Heme oxygenase 1; Inflammation; Lansoprazole; NF E2 related factor 2; Proton pump

Indexed keywords

FAMOTIDINE; HEME OXYGENASE 1; INDOMETACIN; KELCH LIKE ECH ASSOCIATED PROTEIN 1; LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; TRANSCRIPTION FACTOR NRF2;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL PROTECTION; DIGESTIVE SYSTEM INFLAMMATION; DRUG MECHANISM; EPITHELIUM CELL; IN VITRO STUDY; INFLAMMATION; INFLAMMATORY CELL; INTESTINE ISCHEMIA; INTESTINE MUCOSA; NONHUMAN; PROTEIN EXPRESSION; REPERFUSION INJURY;

RATTUS;

EID: 77953387275     PISSN: None     EISSN: 19381247     Source Type: Journal    
DOI: 10.4255/mcpharmacol.10.08     Document Type: Article

References (47)

1. Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 2008;64:935-51.
2. Johnson DA, Katz PO. Nocturnal gastroesophageal reflux disease: issues, implications, and management strategies. Rev Gastroenterol Disord 2008;8:98-108.
3. Hongo M, Kinoshita Y, Miwa H, Ashida K. The demographic characteristics and health-related quality of life in a large cohort of reflux esophagitis patients in Japan with reference to the effect of lansoprazole: the REQUEST study. J Gastroenterol 2008;43:920-7.
4. Kusunoki H, Kusaka M, Kido S, et al. Comparison of the effects of omeprazole and famotidine in treatment of upper abdominal symptoms in patients with reflux esophagitis. J Gastroenterol 2009;44:261-70.
5. Iwakiri K, Kawami N, Sano H, et al. Acid and non-acid reflux in Japanese patients with non-erosive reflux disease with persistent reflux symptoms, despite taking a double-dose of proton pump inhibitor: a study using combined pH-impedance monitoring. J Gastroenterol 2009;44:708-12.
6. Ho KY, Kuan A, Zano F, et al. Randomized, parallel, double-blind comparison of the ulcer-healing effects of ilaprazole and omeprazole in the treatment of gastric and duodenal ulcers. J Gastroenterol 2009;44:697-707.
7. Nishizawa T, Suzuki H, Hibi T. Quinolone-based third-line therapy for Helicobacter pylori eradication. J Clin Biochem Nutr 2009;44:119-24.
8. Yoshida N, Uchiyama K, Kuroda M, et al. Interleukin-8 expression in the esophageal mucosa of patients with gastroesophageal reflux disease. Scand J Gastroenterol 2004;39:816-22.
9. Isomoto H, Nishi Y, Wang A, et al. Mucosal concentrations of proinflammatory cytokines and chemokines at gastric cardia: implication of Helicobacter pylori infection and gastroesophageal reflux. Am J Gastroenterol 2004;99:1063-8.
10. Isomoto H, Nishi Y, Kanazawa Y, et al. Immune and Inflammatory Responses in GERD and Lansoprazole. J Clin Biochem Nutr 2007;41:84-91.
11. Ichikawa H, Yoshida N, Takagi T, et al. Lansoprazole ameliorates intestinal mucosal damage induced by ischemia-reperfusion in rats. World J Gastroenterol 2004;10:2814-7.
12. Kuroda M, Yoshida N, Ichikawa H, et al. Lansoprazole, a proton pump inhibitor, reduces the severity of indomethacin-induced rat enteritis. Int J Mol Med 2006;17:89-93.
13. Higuchi K, Yoda Y, Amagase K, et al. Prevention of NSAID-induced small intestinal mucosal injury: prophylactic potential of lansoprazole. J Clin Biochem Nutr 2009;45:125-30.
14. Hendriks HJ, van Kreel B, Forget PP. Effects of therapy with lansoprazole on intestinal permeability and inflammation in young cystic fibrosis patients. J Pediatr Gastroenterol Nutr 2001;33:260-5.
15. Ohara T, Morishita T, Suzuki H, et al. Investigation of the possibility of human-beta defensin 2 (hBD2) as a molecular marker of gastric mucosal inflammation. Hepatogastroenterology 2005;52:1320-4.
16. Naito Y. Anti-inflammatory and anti-oxidative properties of proton pump inhibitors. J Clin Biochem Nutr 2007;41:82-83.
17. Becker JC, Grosser N, Waltke C, et al. Beyond gastric acid reduction: proton pump inhibitors induce heme oxygenase-1 in gastric and endothelial cells. Biochem Biophys Res Commun 2006;345:1014-21.
18. Shibahara S. Regulation of heme oxygenase gene expression. Semin Hematol 1988;25:370-376.
19. Sassa S. Biological implication of heme metabolism. J Clin Biochem Nutr 2006;38:138-155.
20. Igarashi K, Sun J. The heme-Bach1 pathway in the regulation of oxidative stress response and erythroid differentiation. Antioxid Redox Signal 2006;8:107-18.
21. Lim HJ, Lee KS, Lee S, et al. 15d-PGJ2 stimulates HO-1 expression through p38 MAP kinase and Nrf-2 pathway in rat vascular smooth muscle cells. Toxicol Appl Pharmacol 2007;223:20-7.
22. Ferrandiz ML, Devesa I. Inducers of heme oxygenase-1. Curr Pharm Des 2008;14:473-86.
23. Morse D, Lin L, Choi AM, Ryter SW. Heme oxygenase-1, a critical arbitrator of cell death pathways in lung injury and disease. Free Radic Biol Med 2009;47:1-12.
24. Takagi T, Naito Y, Okada H, et al. Lansoprazole, a proton pump inhibitor, mediates anti-inflammatory effect in gastric mucosal cells through the induction of heme oxygenase-1 via activation of NF-E2-related factor 2 and oxidation of kelch-like ECH-associating protein 1. J Pharmacol Exp Ther 2009;331:255-64.
25. Yoshida N, Yoshikawa T, Tanaka Y, et al. A new mechanism for anti-inflammatory actions of proton pump inhibitors-inhibitory effects on neutrophil-endothelial cell interactions. Aliment Pharmacol Ther 2000;14 Suppl 1:74-81.
26. Handa O, Yoshida N, Fujita N, et al. Molecular mechanisms involved in anti-inflammatory effects of proton pump inhibitors. Inflamm Res 2006;55:476-80.
27. Hinoki A, Yoshimura K, Fujita K, et al. Suppression of proinflammatory cytokine production in macrophages by lansoprazole. Pediatr Surg Int 2006;22:915-23.
28. Hashioka S, Klegeris A, McGeer PL. Proton pump inhibitors exert anti-inflammatory effects and decrease human microglial and monocytic THP-1 cell neurotoxicity. Exp Neurol 2009;217:177-83.
29. Tanigawa T, Watanabe T, Higuchi K, et al. Lansoprazole, a Proton pump inhibitor, suppresses production of tumor necrosis factor-alpha and interleukin-1beta induced by lipopolysaccharide and Helicobacter pylori bacterial components in human monocytic cells via inhibition of activation of nuclear factor-kappaB and extracellular signal-regulated kinase. J Clin Biochem Nutr 2009;45:86-92.
30. Nakamura M, Matsui H, Serizawa H, Tsuchimoto K. Lansoprazole novel effector sites revealed by autoradiography: relation to Helicobacter pylori, colon, esophagus and others. J Clin Biochem Nutr 2007;41:154-9.
31. Handa O, Naito Y, Takagi T, et al. Tumor necrosis factor-alpha-induced cytokine-induced neutrophil chemoattractant-1 (CINC-1) production by rat gastric epithelial cells: role of reactive oxygen species and nuclear factor-kappaB. J Pharmacol Exp Ther 2004;309:670-6.
32. Harusato A, Naito Y, Takagi T, et al. Inhibition of BACH1 ameliorates indomethacin-induced intestinal injury in mice. J Pharm Pharmacol 2010; in press.
33. Alam J, Stewart D, Touchard C, et al. Nrf2, a Cap'n'Collar transcription factor, regulates induction of the heme oxygenase-1 gene. J Biol Chem 1999;274:26071-8.
34. Itoh K, Wakabayashi N, Katoh Y, et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 1999;13:76-86.
35. Ishii T, Itoh K, Takahashi S, et al. Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J Biol Chem 2000;275:16023-9.
36. Itoh K, Wakabayashi N, Katoh Y, et al. Keap1 regulates both cytoplasmic-nuclear shuttling and degradation of Nrf2 in response to electrophiles. Genes Cells 2003;8:379-91.
37. Ryter SW, Choi AM. Heme oxygenase-1: redox regulation of a stress protein in lung and cell culture models. Antioxid Redox Signal 2005;7:80-91.
38. Choi MA, Kim BS, Yu R. Serum antioxidative vitamin levels and lipid peroxidation in gastric carcinoma patients. Cancer Lett 1999;136:89-93.
39. Gong P, Cederbaum AI, Nieto N. Increased expression of cytochrome P450 2E1 induces heme oxygenase-1 through ERK MAPK pathway. J Biol Chem 2003;278:29693-700.
40. Schwer CI, Guerrero AM, Humar M, et al. Heme oxygenase-1 inhibits the proliferation of pancreatic stellate cells by repression of the extracellular signal-regulated kinase1/2 pathway. J Pharmacol Exp Ther 2008;327:863-71.
41. Ning W, Song R, Li C, et al. TGF-beta1 stimulates HO-1 via the p38 mitogen-activated protein kinase in A549 pulmonary epithelial cells. Am J Physiol Lung Cell Mol Physiol 2002;283:L1094-102.
42. Pi J, Zhang Q, Woods CG, et al. Activation of Nrf2-mediated oxidative stress response in macrophages by hypochlorous acid. Toxicol Appl Pharmacol 2008;226:236-43.
43. Dhakshinamoorthy S, Jaiswal AK. Functional characterization and role of INrf2 in antioxidant response element-mediated expression and antioxidant induction of NAD(P)H:quinone oxidoreductase1 gene. Oncogene 2001;20:3906-17.
44. Dinkova-Kostova AT, Holtzclaw WD, Cole RN, et al. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc Natl Acad Sci U S A 2002;99:11908-13.
45. Zhang DD, Hannink M. Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol Cell Biol 2003;23:8137-51.
46. Ishii T, Uchida K. Induction of reversible cysteine-targeted protein oxidation by an endogenous electrophile 15-deoxy-delta12,14-prostaglandin J2. Chem Res Toxicol 2004;17:1313-22.
47. Yamamoto T, Suzuki T, Kobayashi A, et al. Physiological significance of reactive cysteine residues of Keap1 in determining Nrf2 activity. Mol Cell Biol 2008;28:2758-70.